Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Renata Rao

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|July 17, 2008
Cerebrovascular risk factors and MRI abnormalities in migraineRenata Rao, Anna Rosati, Paolo Liberini, et al.
European Neurology|December 20, 2022
Migraine Disability and Severity Improvement during Long-Term Treatment with ErenumabMarco Bolchini, Francesca Schiano di Cola, Giulia Ceccardi, et al.
Frontiers in Neurology|February 6, 2023
Photophobia and migraine outcome during treatment with galcanezumabFrancesca Schiano di Cola, Giulia Ceccardi, Marco Bolchini, et al.
Toxins|December 22, 2023
Onabotulinumtoxin-A: Previous Prophylactic Treatment Might Improve Subsequent Anti-CGRP Monoclonal Antibodies Response in Patients with Chronic MigraineGiulia Ceccardi, Francesca Schiano di Cola, Salvatore Caratozzolo, et al.
The Journal of Headache and Pain|December 20, 2005
Functional serotonin 5-HTTLPR polymorphism is a risk factor for migraine with auraBarbara Borroni, Cristina Brambilla, Paolo Liberini, et al.
Headache|February 24, 2006
Investigating the association between Notch3 polymorphism and migraineBarbara Borroni, Cristina Brambilla, Paolo Liberini, et al.
Neurology International|February 22, 2023
Migraine Disability Improvement during Treatment with Galcanezumab in Patients with Chronic and High Frequency Episodic MigraineFrancesca Schiano di Cola, Marco Bolchini, Salvatore Caratozzolo, et al.
Journal of Neurology|January 7, 2014
A follow-up ¹⁸F-FDG brain PET study in a case of Hashimoto's encephalopathy causing drug-resistant status epilepticus treated with plasmapheresisElisa Pari, Fabrizio Rinaldi, Enrico Premi, et al.
European Journal of Neurology|January 2, 2024
Increased risk of functional neurological disorders following SARS-CoV-2 vaccinationAndrea Pilotto, Marcello Catania, Irene Mattioli, et al.
Frontiers in Pain Research (Lausanne, Switzerland)|November 25, 2022
Post COVID-19 vaccination headache: A clinical and epidemiological evaluationGiulia Ceccardi, Francesca Schiano di Cola, Marco Di Cesare, et al.
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|July 17, 2008
Cerebrovascular risk factors and MRI abnormalities in migraineRenata Rao, Anna Rosati, Paolo Liberini, et al.
European Neurology|December 20, 2022
Migraine Disability and Severity Improvement during Long-Term Treatment with ErenumabMarco Bolchini, Francesca Schiano di Cola, Giulia Ceccardi, et al.
Frontiers in Neurology|February 6, 2023
Photophobia and migraine outcome during treatment with galcanezumabFrancesca Schiano di Cola, Giulia Ceccardi, Marco Bolchini, et al.
Toxins|December 22, 2023
Onabotulinumtoxin-A: Previous Prophylactic Treatment Might Improve Subsequent Anti-CGRP Monoclonal Antibodies Response in Patients with Chronic MigraineGiulia Ceccardi, Francesca Schiano di Cola, Salvatore Caratozzolo, et al.
The Journal of Headache and Pain|December 20, 2005
Functional serotonin 5-HTTLPR polymorphism is a risk factor for migraine with auraBarbara Borroni, Cristina Brambilla, Paolo Liberini, et al.
Headache|February 24, 2006
Investigating the association between Notch3 polymorphism and migraineBarbara Borroni, Cristina Brambilla, Paolo Liberini, et al.
Neurology International|February 22, 2023
Migraine Disability Improvement during Treatment with Galcanezumab in Patients with Chronic and High Frequency Episodic MigraineFrancesca Schiano di Cola, Marco Bolchini, Salvatore Caratozzolo, et al.
Journal of Neurology|January 7, 2014
A follow-up ¹⁸F-FDG brain PET study in a case of Hashimoto's encephalopathy causing drug-resistant status epilepticus treated with plasmapheresisElisa Pari, Fabrizio Rinaldi, Enrico Premi, et al.
European Journal of Neurology|January 2, 2024
Increased risk of functional neurological disorders following SARS-CoV-2 vaccinationAndrea Pilotto, Marcello Catania, Irene Mattioli, et al.
Frontiers in Pain Research (Lausanne, Switzerland)|November 25, 2022
Post COVID-19 vaccination headache: A clinical and epidemiological evaluationGiulia Ceccardi, Francesca Schiano di Cola, Marco Di Cesare, et al.
Pageof 4